Tumor Lysis Syndrome (TLS)

Tumor Lysis Syndrome (TLS) is a serious condition that happens when a large number of cancer cells die quickly, releasing their contents into the bloodstream. This sudden release affects the body's kidneys and electrolyte balance, leading to problems like high levels of uric acid, potassium, and phosphate. These changes can cause symptoms such as muscle cramps, weakness, irregular heartbeat, and kidney failure. The condition mainly involves the blood and urinary systems because the kidneys struggle to filter the excess substances. It often occurs after starting treatment for cancers like leukemia or lymphoma. The rapid cell breakdown overwhelms the body's ability to maintain normal chemical levels, which can be life-threatening if not managed promptly.

Tumor Lysis Syndrome (TLS) is an oncologic emergency characterized by massive and rapid destruction of malignant cells, typically following initiation of cytotoxic therapy in high-grade hematologic malignancies such as acute leukemias and high-burden lymphomas. The core pathology involves the release of intracellular ions and metabolic byproducts, including potassium, phosphate, and nucleic acids, which are metabolized to uric acid. This leads to hyperkalemia, hyperphosphatemia, hyperuricemia, and secondary hypocalcemia due to phosphate binding calcium. The resulting metabolic disturbances can cause acute kidney injury, cardiac arrhythmias, seizures, and death. Recognition of TLS is critical due to its rapid onset and potential for severe complications. The syndrome reflects a failure of renal excretion and metabolic homeostasis in response to tumor cell lysis.